ACADIA Pharmaceuticals Inc. (ACAD) — Fair Value Analysis
Base-case fair value (P50): $34.63 · Current price: $23.49 · Verdict: Undervalued
The Verdict on ACAD
Our Monte Carlo simulations indicate that ACADIA PHARMACEUTICALS INC (ACAD) is Deeply Undervalued at its current market price of $23.49. The median fair value (P50) derived from thousands of forward scenarios stands at $34.63, suggesting a substantial +47.4% potential. This valuation contrasts sharply with the present market cap, signaling a significant disconnect that investors should note. The simulations robustly account for various market conditions and company-specific variables, consistently pointing towards a considerable upside from the $23.49. This deep undervaluation, based on our rigorous modeling, makes ACAD a compelling target for further scrutiny, despite its average quality tier compared to the broader sector.
How ACAD stacks up against Healthcare
Within the Healthcare sector, ACAD's operational and financial health is categorized as average. While this indicates it performs competently against its peers, its Deeply Undervalued status is primarily driven by the disconnect between the intrinsic value generated by our simulations and the current market's perception. The median fair value of $34.63 significantly surpasses the $23.49, showcasing that even an average quality tier company can present significant alpha opportunities when priced incorrectly by the market. Investors seeking value within Healthcare should consider how ACAD's compelling +47.4% potential, as identified by our simulations, stands out, irrespective of its average quality tier.
What this means for investors
The considerable +47.4% implied by our Monte Carlo analysis, with a P50 fair value of $34.63 versus the current market price of $23.49, presents a clear opportunity. For investors, this suggests that the market may not be fully appreciating ACAD's future cash flow potential. While an upside scenario is projected, a downside scenario remains a possibility, as with any equity. Our simulations, however, overwhelmingly support a positive outlook. To fully understand the range of potential outcomes for ACAD, including bear and bull case distributions and probability analyses, sign up for a free FairCurve account to see the full Monte Carlo distribution and track ACAD's fair value as new fundamentals are released.
Frequently Asked Questions
Is ACAD overvalued or undervalued right now?
Based on our Monte Carlo simulations, ACAD is currently deeply undervalued. Its median fair value (P50) of $34.63 is significantly higher than its current market price of $23.49.
What is the bear case and bull case for ACAD?
The full Monte Carlo distribution, including specific bear (P10) and bull (P90) target prices, along with the probability of achieving upside, is available with a free FairCurve account.
How does FairCurve calculate ACAD's fair value?
FairCurve employs Monte Carlo simulation to estimate ACAD's fair value by running thousands of forward-looking scenarios, incorporating various financial and operational assumptions.
How can I track ACAD's fair value as it changes?
You can add ACAD to a free FairCurve watchlist to receive daily fair-value updates and instant re-valuation whenever new earnings or significant company fundamentals are released.